Addus HomeCare Corporation
NASDAQ:ADUSMedical - Care Facilities
+$0.29 today
- Market cap
- $2.25B
- Beta
- 0.90
- P/E (TTM)
- 17.4
- EPS (TTM)
- $5.40
Volume 0.23M
Average 0.25M
ADUS Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Addus HomeCare CorporationNASDAQ: ADUS
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development remains negative
Q2 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.
Context
- Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Research & Development vs competitors
How ADUS compares with its peers on the latest reported figures
- ADUS's LTM Jun 2026 research & development of $0 is the highest of the 7 companies compared; the peer median is $0.
- Research & development amounts to 0.0% of revenue for ADUS, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Sep 2026 | $0 | — | — | 0.0% | |
| LTM Oct 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding ADUS) | $0 | — | — | 0.0% | |
Competitors are the stored peer set for ADUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 864.5M | 951.12M | 1.06B | 1.15B | 1.42B |
| Cost of Revenue | 595.24M | 651.38M | 718.78M | 779.58M | 960.66M |
| Gross Profit | 269.85M | 299.74M | 339.88M | 375.02M | 461.87M |
| Gross Margin | 31.2% | 31.5% | 32.1% | 32.5% | 32.5% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 189.42M | 216.94M | 231.68M | 258.8M | 306.85M |
| Operating Expenses | 203.32M | 231M | 248.92M | 272.33M | 323.26M |
| Depreciation & Amortization | 14.49M | 14.06M | 14.13M | 13.53M | 16.41M |
| EBITDA | 80.7M | 83.14M | 106.56M | 120.62M | 153.44M |
| EBITDA Margin | 9.3% | 8.7% | 10.1% | 10.4% | 10.8% |
| Operating Income | 65.94M | 68.74M | 90.96M | 102.69M | 138.62M |
| Operating Margin | 7.6% | 7.2% | 8.6% | 8.9% | 9.7% |
| Interest Income | 268K | 341K | 1.48M | 4.39M | 1.59M |
| Interest Expense | 5.81M | 8.91M | 11.11M | 7.73M | 9.58M |
| Other Income / Expenses | (5.54M) | (8.57M) | (9.63M) | (3.34M) | (11.17M) |
| Income Before Tax | 60.4M | 60.17M | 81.33M | 99.35M | 127.45M |
| Pre-Tax Margin | 7.0% | 6.3% | 7.7% | 8.6% | 9.0% |
| Income Tax Expense | 15.27M | 14.15M | 18.81M | 25.76M | 31.54M |
| Net Income | 45.13M | 46.03M | 62.52M | 73.6M | 95.91M |
| Net Margin | 5.2% | 4.8% | 5.9% | 6.4% | 6.7% |
| EPS (Basic) | 2.87 | 2.90 | 3.91 | 4.33 | 5.19 |
| EPS (Diluted) | 2.81 | 2.84 | 3.83 | 4.23 | 5.21 |
| Weighted Avg Shares | 15.74M | 16.13M | 16.23M | 17.01M | 18.45M |
| Weighted Avg Shares (Diluted) | 16.06M | 16.18M | 16.31M | 17.38M | 18.45M |
Addus HomeCare Corporation
NASDAQ:ADUS
Intrinsic Alpha fair value
Locked
Current Price
$120.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.